Literature DB >> 2469338

Hypertonic saline-dextran solutions for the prehospital management of traumatic hypotension.

P A Maningas1, K L Mattox, P E Pepe, R L Jones, D V Feliciano, J M Burch.   

Abstract

We report the results of the first clinical study on the use of a hypertonic saline-dextran solution for the prehospital management of hypotensive victims of penetrating trauma. During a 4-month period, 48 trauma patients with penetrating injuries and a prehospital systolic blood pressure of 90 mm Hg or less were infused in-field with 250 ml of either a hypertonic saline-dextran solution or the crystalloid plasmalyte A. There were no complications associated with the infusion of the hypertonic saline-dextran solution, and execution of the protocol by paramedic personnel was both safe and uniformly successful. The potential impact of this solution on medical care and the results of this feasibility study justify the initiation of a larger prospective, randomized clinical trial on the efficacy of this solution in the prehospital setting.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469338     DOI: 10.1016/0002-9610(89)90654-5

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  17 in total

1.  Considerations in the surgical treatment of congenital heart disease in children of Jehovah's Witnesses.

Authors:  D A Cooley; C M Burnett
Journal:  Tex Heart Inst J       Date:  1992

Review 2.  Retroelements and formation of chimeric retrogenes.

Authors:  A A Buzdin
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

Review 3.  Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: A meta-analysis of the literature.

Authors:  R De Vecchis; C Esposito; C Ariano; S Cantatrione
Journal:  Herz       Date:  2014-03-30       Impact factor: 1.443

4.  [Renoprotective effect of small volumes of hypertonic saline solution in chronic heart failure patients with marked fluid retention: results of a case-control study].

Authors:  R De Vecchis; A Ciccarelli; C Ariano; A Pucciarelli; C Cioppa; A Giasi; A Fusco; S Cantatrione
Journal:  Herz       Date:  2010-10-28       Impact factor: 1.443

Review 5.  Intravenous Fluid Therapy in Traumatic Brain Injury and Decompressive Craniectomy.

Authors:  Hernando Raphael Alvis-Miranda; Sandra Milena Castellar-Leones; Luis Rafael Moscote-Salazar
Journal:  Bull Emerg Trauma       Date:  2014-01

6.  Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial.

Authors:  Eileen M Bulger; Susanne May; Jeffery D Kerby; Scott Emerson; Ian G Stiell; Martin A Schreiber; Karen J Brasel; Samuel A Tisherman; Raul Coimbra; Sandro Rizoli; Joseph P Minei; J Steven Hata; George Sopko; David C Evans; David B Hoyt
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

7.  Small-volume hypertonic saline dextran resuscitation from canine endotoxin shock.

Authors:  J W Horton; P B Walker
Journal:  Ann Surg       Date:  1991-07       Impact factor: 12.969

8.  Collider bias in trauma comparative effectiveness research: the stratification blues for systematic reviews.

Authors:  Deborah J Del Junco; Eileen M Bulger; Erin E Fox; John B Holcomb; Karen J Brasel; David B Hoyt; James J Grady; Sarah Duran; Patricia Klotz; Michael A Dubick; Charles E Wade
Journal:  Injury       Date:  2015-01-31       Impact factor: 2.586

9.  Blood loss and transcapillary refill in uncontrolled treated hemorrhage in dogs.

Authors:  Elias Aissar Sallum; Sueli Sinozaki; Ana Maria Calil; Raul Coimbra; Maurício Rocha E Silva; Luis Francisco Poli de Figueiredo; Dario Birolini
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

10.  Influence of hypertonic-hyperoncotic solution and furosemide on canine hydrostatic pulmonary oedema resorption.

Authors:  C J Wickerts; B Berg; C Frostell; J Schmidt; H Blomqvist; P G Rösblad; I Kihlström; K Messmer; G Hedenstierna
Journal:  J Physiol       Date:  1992-12       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.